Influenza Immunization in Adults Over Age 75
NCT02200276 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1025
Last updated 2026-03-16
Summary
The immune system is the part of the body that protects against infection. The immune system often doesn't work as effectively as people get older. This research is being done to find out how the immune systems in older people who are over age 75 respond to influenza vaccine (flu shot). We also want to find out if chronic cytomegalovirus (CMV) infection, a common virus infection in older persons affects the immune response in people older than 75 years of age who receive a flu shot. The Flu Shot is a vaccine approved for the prevention of influenza ("Flu") infections and is recommended every year for all persons 50 years and older. People who are older than 75 years of age are considered healthy or frail may join. A total of 1025 persons will be participating in this study.
In order to determine if you are qualified for the study, we would ask you to answer a few questions over the phone that will take approximately 5 minutes. If you qualify and agree to proceed, you will be asked to come to Johns Hopkins Bayview Medical Center or, if you are unable to come to Bayview, one of our staff can visit you at your home. During that visit we obtain consent, review your medical history, and measure your vital signs, walking speed and grip strength. We will also administer a few brief questionnaires and collect urine and blood samples. We will then give you the Influenza vaccine for free. 7 days post receiving your Influenza Vaccine we will collect a small blood sample for further immune system testing. also, you will be asked to complete a 12-question survey which will assess your symptoms over the past 7 days (post receiving the Influenza vaccine). Also 4 weeks post receiving your Influenza vaccine you will be asked to complete a third visit that will include follow up health questionnaires and an influenza symptoms assessment questionnaire and vital signs. A third blood draw will be collected (approximately 10 teaspoons) to measure immune responses to the influenza vaccine. In addition, you will receive your test result (CBC/w/Diff.) from visit #1. Throughout the influenza study season, we will call you once a week to ask about your general health and any Flu-like symptoms. These calls will be made throughout the Flu season which typically lasts through May. If you begin to have any influenza like symptoms at any time during the study, we ask that you call our office to report these symptoms so that we may perform vital signs, nasal swab to confirm influenza, and a fourth blood draw to look at the immune response and protection of influenza vaccine.
Conditions
- Influenza
- Immunization
- Older Adults
- Over Age 75
Interventions
- BIOLOGICAL
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Sean Leng · Johns Hopkins University
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-03-31
- Primary Completion
- 2026-11-30
- Completion
- 2027-11-30
Countries
- United States
Study Locations
More Related Trials
-
Immune Response to High-Dose vs. Standard Dose Influenza Vaccine
NCT02297542 ·Status: UNKNOWN ·Phase: PHASE4
-
A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers
NCT01010737 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
NCT05291676 ·Status: RECRUITING ·Phase: PHASE2
-
Immune Response to Influenza Vaccination
NCT00551837 ·Status: COMPLETED
-
Elderly Influenza Vaccine Immunogenicity Substudy
NCT00170482 ·Status: COMPLETED
-
A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
NCT05823974 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults
NCT02401893 ·Status: COMPLETED
-
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
NCT01766921 ·Status: COMPLETED ·Phase: PHASE2
-
Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients
NCT02623075 ·Status: COMPLETED
-
Immune Response Study of Influenza Vaccine
NCT01310374 ·Status: COMPLETED
-
Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults
NCT01967368 ·Status: UNKNOWN ·Phase: PHASE4
-
Inactivated Influenza A/H5N1 Vaccine in the Elderly
NCT00230750 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Revealing Protective Immunity to Influenza Using Systems Immunology
NCT06501963 ·Status: COMPLETED ·Phase: PHASE4
-
Immune and Hormone Response to Influenza Vaccine
NCT01978262 ·Status: COMPLETED ·Phase: PHASE4
-
DNA-based Influenza Vaccine in the Elderly
NCT01587131 ·Status: COMPLETED ·Phase: PHASE1
-
Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly
NCT01232868 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older
NCT00760617 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly
NCT01013675 ·Status: COMPLETED ·Phase: PHASE2
-
Influenza Vaccination Among the Elderly Individuals
NCT02362919 ·Status: COMPLETED
-
Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study
NCT01522248 ·Status: COMPLETED ·Phase: NA
-
Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection
NCT06401720 ·Status: ENROLLING_BY_INVITATION
-
A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
NCT06431607 ·Status: COMPLETED ·Phase: PHASE2
-
The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
NCT02876159 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
NCT00845429 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults
NCT04782323 ·Status: COMPLETED ·Phase: PHASE2